Preemptive rapid antigen test as an emergency measure during coronavirus disease 2019 outbreaks

在2019冠状病毒病疫情爆发期间,将快速抗原检测作为一项紧急措施。

阅读:3

Abstract

BACKGROUND: We acknowledge that the rapid antigen test (RAT) has several advantages, including faster results, cost-effectiveness, and suitability for on-site self-testing. However, there is still controversy regarding the performance of the RAT for coronavirus disease 2019 (COVID-19). The aim of this study was to evaluate RAT screening in a COVID-19 outbreak situation. METHODS: In this study, we developed a preemptive testing model in which a RAT was immediately followed by reverse transcriptase polymerase chain reaction (RT-PCR) during a single screening in a high-density community outbreak to rapidly prevent transmission. The RAT and RT-PCR were performed using the Flowflex(™) SARS-CoV-2 Antigen Test Kit and the SARS-CoV-2 Nucleic Acid Test Kit, respectively. Furthermore, we retrospectively investigated diagnostic data from a total of 813 participants. Then, we analyzed sensitivity and specificity using RT-PCR as the reference method. In addition, we compared our data with those from another published study involving serial screening using the chi-squared test, in which 541 samples were analyzed. RESULTS: Our study showed that the sensitivity and specificity of the RAT were 0.82 and 1.00, respectively. We found a slightly higher false-negative rate, corresponding to decreased sensitivity, in our data compared to the previous study; however, the difference was not statistically significant. In addition, there was no statistically significant difference in the false-positive rate, corresponding to specificity, between the two studies. CONCLUSION: The current results indicate that a RAT with a single screening does not pose an additional risk of inaccurate diagnosis of COVID-19 compared to serial screening. The strategy of a preemptive RAT might be an effective emergency measure to prevent COVID-19 transmission at an early stage of an outbreak.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。